Abu Dhabi's Mubadala re-invests in its 'top-performing' healthcare asset

Dubai: The Abu Dhabi investment firm Mubadala is putting in more funds into US-based PCI Pharma services, a leading player in contract manufacturing of biotherapies.

The Mubadala investment is part of a transaction co-led by Bain Capital and existing lead investor Kohlberg. (The Partners Group is putting in a minority investment.)

Mubadala has been widening its portfolio of healthcare investments. Within this, PCI is already one of the UAE company's 'top-performing' investments. Mubadala made its initial buy in PCI alongside Kohlberg in 2020.

For Mubadala, this is the second major deal announced this week.

Over the past five years, PCI has had more than 450 product launches and 'continues to build on its 50-year track record in pharmaceutical services'.  

“PCI Pharma Services... is a testament to what can be achieved when long-term active investors partner with strong management teams to catalyze growth, create value, and deliver better patient outcomes worldwide," said Camilla Languille, co-CEO of Private Equity at Mubadala.

"Our team will continue to focus on similar opportunities in the healthcare space as the sustained outsourcing of mission-critical - but non-core - activities by pharma companies aligns with our commitment to address global unmet clinical needs, reduce the cost of care to the system, and enable greater access.”

The new capital will enable PCI to focus on 'both organic and inorganic growth initiatives'. That will mean expanding its services and geographic reach. 

"PCI’s future investments will include expansion of existing sterile fill-finish of injectables and high potent and specialized manufacturing capacity," the statement said. 

"The investment will also enable the company’s significant continued investment in the US, bolstering the nation’s critical pharmaceutical manufacturing and supply chain infrastructure."